Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | HTR6 | P50406 | 7/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BRD1 | O95696 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316971 | 0.96 | F2 (0.37) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3298096 | 0.88 | F2 (0.39) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3298929 | 0.86 | F2 (0.35) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10317266 | 0.86 | F2 (0.38) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13390112 | 0.83 | DGAT1 (0.32) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10318655 | 0.83 | F2 (0.36) | F2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13409455 | 0.83 | F2 (0.30) | F2 | |
| SCHEMBL4553849 | 0.83 | F2 (0.32) | F2 | |
| SCHEMBL3295640 | 0.81 | DGAT1 (0.30) | F2 | |
| SCHEMBL3298886 | 0.80 | ROCK1 (0.31) | BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | F2 4135/4885PSEN1 167/4885PSEN2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.